Assessing the Impact of Genratest on Women With Recurrent Implantation Failure: A Single-Center Study

TL;DR

This study evaluated whether Genratest improves pregnancy outcomes in women with recurrent implantation failure but found no significant differences between personalized and standard embryo transfer methods.

Contribution

The study provides new evidence on the effectiveness of Genratest in clinical pregnancy outcomes for RIF patients.

Findings

Genratest identified a displaced window of implantation in 90% of RIF patients.

Personalized embryo transfer did not significantly improve clinical pregnancy, ongoing pregnancy, or live birth rates compared to standard transfer.

Miscarriage rates were similar between the two groups.

Abstract

Objective

Recurrent implantation failure (RIF) is a significant challenge in assisted reproduction. Genratest has emerged as a potential tool to identify the displaced window of implantation (WOI). This study aimed to evaluate the impact of this test on the pregnancy outcomes of RIF patients.

Methods

A retrospective analysis was conducted on 143 RIF patients who were categorized into two groups: the personalized embryo transfer (pET, n=69) group and standard embryo transfer (sET, n=74) group. The main measured outcomes were clinical pregnancy, ongoing pregnancy, miscarriage, and live birth rates.

Results

Genratest effectively diagnoses the displaced WOI in 90% of RIF patients. The pET group exhibited a higher rate of clinical pregnancy (n=36/69, 52.2%) compared to the sET group (n=35/74, 47.3%), but this difference was not statistically significant (p=0.679). Ongoing pregnancy rates were comparable between the pET (n=28/69, 40.6%) and the sET (n=30/74, 40.5%) groups (p=0.996). Live birth rates showed no statistically significant difference between the two groups (n=26/69, 37.7% versus n=22/74, 29.7%, p=0.407). Miscarriage rates were similar in both groups (n=9/69, 13% versus n=11/74, 14.9%, p=0.942).

Conclusions

pET based on the results of the Genratest did not show a significant improvement in pregnancy outcomes, including clinical pregnancy, ongoing pregnancy, live birth, or miscarriage rates. Further research is needed to identify the role of Genratest in RIF patients.